Business
AI-Driven Stock Analysis Puts J&J in the Spotlight
Leerink analysts upgraded Johnson & Johnson shares to a buy equivalent from hold, citing the company's new drug pipeline. This positive outlook has caught traders' attention amid an AI-driven market.
Coverage timeline — 1 article
CNBC
Leerink analysts lifted J&J shares to a buy equivalent from hold on Wednesday, citing the company's slate of new drugs.
2026-05-13 17:26 UTC